1. Scrip

Takeda Lays Out Teva JV Impact, Confirms Blopress Transfer

 
• By Ian Haydock

Takeda has identified its first mature products to be transferred next April to a new joint venture with Teva, in a transaction it expects to be cash flow accretive next fiscal year despite an initial hit on revenues and operating profit.

TOKYO - As predicted by PharmAsia News when the Takeda Pharmaceutical Co. Ltd.-Teva Pharmaceutical Industries Ltd. off-patent and generic product joint venture in Japan was first announced, Takeda is to transfer to the new operation its big-selling antihypertensive Blopress (candesartan).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

More from Focus On Asia